FDAnews Drug Daily Bulletin

Pfizer to Buy OTC Rights to Nexium for $250 Million Upfront

Aug. 15, 2012
A A
Pfizer has agreed to acquire rights to market AstraZeneca’s popular heartburn drug Nexium for OTC use, paying $250 million up front as well as milestone and royalty payments.
The Wall Street Journal